N-[(1S)-1-(氨基羰基)-4 -[(2 - 氯-1-亚氨基乙基氨基]丁基]-苯甲酰胺
| 中文名称 | N-[(1S)-1-(氨基羰基)-4 -[(2 - 氯-1-亚氨基乙基氨基]丁基]-苯甲酰胺 |
|---|---|
| 中文同义词 | N-[(1S)-1-(氨基羰基)-4 -[(2 - 氯-1-亚氨基乙基氨基]丁基]-苯甲酰胺;N-ALPHA-苯甲酰基-N5-(2-氯-1-亚氨基乙基)-1-鸟氨酰胺;化合物 T10831;(S)-N-(1-氨基-5-(2-氯乙脒)-1-氧代戊烷-2-基)苯甲酰胺 |
| 英文名称 | Cl-Amidine |
| 英文同义词 | Cl-Amidine;N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamideN-;N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]benzamide;N-alpha-Benzoyl-N5-(2-chloro-1-iminoethyl)-1-ornithine amide;Benzamide, N-[(1S)-1-(aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-;Cl amidine,Clamidine;N-BCl-I-OA cpd;(S)-N-(1-Amino-5-(2-chloroacetimidamido)-1-oxopentan-2-yl)benzamide |
| CAS号 | 913723-61-2 |
| 分子式 | C14H19ClN4O2 |
| 分子量 | 310.78 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 913723-61-2.mol |
| 结构式 | ![N-[(1S)-1-(氨基羰基)-4 -[(2 - 氯-1-亚氨基乙基氨基]丁基]-苯甲酰胺 结构式](CAS/20180906/GIF/913723-61-2.gif) |
N-[(1S)-1-(氨基羰基)-4 -[(2 - 氯-1-亚氨基乙基氨基]丁基]-苯甲酰胺 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
IC50: 0.8 μM (PAD1), 5.9 μM (PAD4), 6.2 μM (PAD3).
Cl-amidine is a bioavailable haloacetamidine-based compound that inhibits all the active PAD isozymes with near equal potency (k
inact
/K
I
=13,000 M
-1
•min-1 for PAD4).
Cl-amidine (0, 5, 10, 15, 20, 25, 50 μg/mL, 24 hours) induces apoptosis in TK6 lymphoblastoid cells and HT29 colon cancer cells in a dose-dependent manner. Interestingly, the colon cancer cell line (HT29) is relatively resistant to apoptosis caused by Cl-amidine.
Cl-amidine irreversibly inactivates PADs by covalently modifying an active site cysteine that is important for its catalytic activity.
Apoptosis Analysis.
| Cell Line: | TK6 lymphoblastoid cells and HT29 colon cancer cells. |
| Concentration: | 0, 5, 10, 15, 20, 25, 50 μg/mL. |
| Incubation Time: | 24 h. |
| Result: | Induced apoptosis dose-dependently. |
Cl-amidine (75 mg/kg, ip once daily) suppresses and treats DSS-induced colitis in mice.
Cl-amidine (5, 25, 75 mg/kg, oral gavage, once daily) leads to significant reductions in the histology scores dose-dependently.
| Animal Model: | C57BL/6 mice (8-12 wk old, DSS mouse model of colitis). |
| Dosage: | 75 mg/kg. |
| Administration: | IP once daily. |
| Result: | Suppressed PAD activity, protein citrullination, and PAD levels in the colon in vivo. |
| Animal Model: | C57BL/6 mice (8-12 wk old, DSS mouse model of colitis). |
| Dosage: | 5, 25, 75 mg/kg. |
| Administration: | Oral gavage once daily. |
| Result: | Led to significant reductions in the histology scores. |